Details:

Alternative Title:
Int J Circumpolar Health
Personal Author:
Livingston, Stephen E ; Townshend-Bulson, Lisa J ; Bruden, Dana J T ; Homan, Chriss E ; Gove, James E ; ... More +
Livingston, Stephen E ; Townshend-Bulson, Lisa J ; Bruden, Dana J T ; Homan, Chriss E ; Gove, James E ; Plotnik, Julia N ; Simons, Brenna C ; Spradling, Philip R ; McMahon, Brian J Less -
Description:
Background

There have been few reports of hepatitis C virus (HCV) treatment results with interferon-based regimens in indigenous populations

Objective

To determine interferon-based treatment outcome among Alaska Native and American Indian (AN/AI) population

Design

In an outcomes study of 1,379 AN/AI persons with chronic HCV infection from 1995 through 2013, we examined treatment results of 189 persons treated with standard interferon, interferon plus ribavirin, pegylated interferon plus ribavirin and triple therapy with a protease inhibitor For individuals treated with pegylated interferon and ribavirin, the effect of patient characteristics on response was also examined

Results

Sustained virologic response (SVR) with standard interferon was 167% (3/18) and with standard interferon and ribavirin was 297% (11/37) Of 119 persons treated with pegylated interferon and ribavirin, 61 achieved SVR (513%), including 10 of 46 with genotype 1 (217%), 38 of 51 with genotype 2 (745%) and 13 of 22 with genotype 3 (591%) By multivariate analysis, SVR in the pegylated interferon group was associated with female sex (p=0002), estimated duration of infection (p=0034) and HCV genotype (p<00001) There was a high discontinuation rate due to side effects in those treated with pegylated interferon and ribavirin for genotype 1 (522%) Seven of 15 genotype 1 patients treated with pegylated interferon, ribavirin and telaprevir or boceprevir achieved SVR (467%)

Conclusions

We had success with pegylated interferon-based treatment of AN/AI people with genotypes 2 and 3 However, there were low SVR and high discontinuation rates for those with genotype 1


Subjects:
[+]
Adult Aged Alaska Alaskan Natives Antiviral Agents Drug Therapy, Combination Female Follow-Up Studies Hepacivirus Hepatitis C, Chronic Humans Indians, North American Interferon-alpha Longitudinal Studies Male Middle Aged Polyethylene Glycols Recombinant Proteins Ribavirin Risk Assessment Treatment Outcome
Source:
Int J Circumpolar Health 2016; 75
Pubmed ID:
27029671
Pubmed Central ID:
PMC4814572
Document Type:
Journal Article
Funding:
U01 PS001097/PS/NCHHSTP CDC HHS/United States ; U01 PS004113/PS/NCHHSTP CDC HHS/United States
U01 PS001097/PS/NCHHSTP CDC HHS/United States ; U01 PS004113/PS/NCHHSTP CDC HHS/United States Less -
Place as Subject:
Alaska
Location:
Alaska
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:66e0f1958cffd38c3a1a77dccfd1972450d12a28078149bb98a129a00e92c6a2
Download URL:
https://stacks.cdc.gov/view/cdc/39194/cdc_39194_DS1.pdf
File Type:

Supporting Files

• IJCH-75-30696.nxml

  bin

More +